Cover Image
市場調查報告書

頭頸癌:開發中產品分析

Head And Neck Cancer - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 351248
出版日期 內容資訊 英文 1639 Pages
訂單完成後即時交付
價格
Back to Top
頭頸癌:開發中產品分析 Head And Neck Cancer - Pipeline Review, H1 2018
出版日期: 2018年04月30日 內容資訊: 英文 1639 Pages
簡介

頭頸癌是在頭部或頸部(鼻腔,副鼻腔,嘴唇,口,唾液腺,喉嚨或喉)等領域發生的癌症。這個癌症的一般症狀有喉嚨的持續性疼痛,伴隨吞嚥的疼痛和困難,持續性的嘶啞聲和聲音變化,耳朵的疼痛,口內和喉嚨出血等。可用化療和放射治療管理。

本報告提供頭頸癌的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

頭頸癌概要

治療藥的開發

頭頸癌:治療藥的評估

頭頸癌治療藥的開發企業

藥物簡介

頭頸癌:暫停中的計劃

頭頸癌:開發中止的產品

頭頸癌:產品開發的里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10354IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer - Pipeline Review, H1 2018, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.

Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 21, 113, 120, 6, 75, 20 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 10, 8, 15, 4 and 1 molecules, respectively.

Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Head And Neck Cancer - Overview
  • Head And Neck Cancer - Therapeutics Development
  • Head And Neck Cancer - Therapeutics Assessment
  • Head And Neck Cancer - Companies Involved in Therapeutics Development
  • Head And Neck Cancer - Drug Profiles
  • Head And Neck Cancer - Dormant Projects
  • Head And Neck Cancer - Discontinued Products
  • Head And Neck Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Table 1: Number of Products under Development for Head And Neck Cancer, H1 2018
  • Table 2: Number of Products under Development by Companies, H1 2018
  • Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Table 9: Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018
  • Table 10: Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018
  • Table 11: Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018
  • Table 12: Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018
  • Table 13: Number of Products under Development by Companies, H1 2018 (Contd..11), H1 2018
  • Table 14: Number of Products under Development by Companies, H1 2018 (Contd..12), H1 2018
  • Table 15: Number of Products under Development by Universities/Institutes, H1 2018
  • Table 16: Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
  • Table 17: Products under Development by Companies, H1 2018
  • Table 18: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 19: Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 20: Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 21: Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Table 22: Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Table 23: Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Table 24: Products under Development by Companies, H1 2018 (Contd..7), H1 2018
  • Table 25: Products under Development by Companies, H1 2018 (Contd..8), H1 2018
  • Table 26: Products under Development by Companies, H1 2018 (Contd..9), H1 2018
  • Table 27: Products under Development by Companies, H1 2018 (Contd..10), H1 2018
  • Table 28: Products under Development by Companies, H1 2018 (Contd..11), H1 2018
  • Table 29: Products under Development by Companies, H1 2018 (Contd..12), H1 2018
  • Table 30: Products under Development by Companies, H1 2018 (Contd..13), H1 2018
  • Table 31: Products under Development by Companies, H1 2018 (Contd..14), H1 2018
  • Table 32: Products under Development by Companies, H1 2018 (Contd..15), H1 2018
  • Table 33: Products under Development by Companies, H1 2018 (Contd..16), H1 2018
  • Table 34: Products under Development by Companies, H1 2018 (Contd..17), H1 2018
  • Table 35: Products under Development by Companies, H1 2018 (Contd..18), H1 2018
  • Table 36: Products under Development by Companies, H1 2018 (Contd..19), H1 2018
  • Table 37: Products under Development by Companies, H1 2018 (Contd..20), H1 2018
  • Table 38: Products under Development by Companies, H1 2018 (Contd..21), H1 2018
  • Table 39: Products under Development by Companies, H1 2018 (Contd..22), H1 2018
  • Table 40: Products under Development by Companies, H1 2018 (Contd..23), H1 2018
  • Table 41: Products under Development by Companies, H1 2018 (Contd..24), H1 2018
  • Table 42: Products under Development by Universities/Institutes, H1 2018
  • Table 43: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
  • Table 44: Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018
  • Table 45: Number of Products by Stage and Target, H1 2018
  • Table 46: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
  • Table 47: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
  • Table 48: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
  • Table 49: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
  • Table 50: Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018
  • Table 51: Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018
  • Table 52: Number of Products by Stage and Target, H1 2018 (Contd..7), H1 2018
  • Table 53: Number of Products by Stage and Target, H1 2018 (Contd..8), H1 2018
  • Table 54: Number of Products by Stage and Mechanism of Action, H1 2018
  • Table 55: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
  • Table 56: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
  • Table 57: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
  • Table 58: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
  • Table 59: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018
  • Table 60: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018
  • Table 61: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..7), H1 2018
  • Table 62: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..8), H1 2018
  • Table 63: Number of Products by Stage and Route of Administration, H1 2018
  • Table 64: Number of Products by Stage and Molecule Type, H1 2018
  • Table 65: Number of Products by Stage and Molecule Type, H1 2018 (Contd..1), H1 2018
  • Table 66: Head And Neck Cancer - Pipeline by 3SBio Inc, H1 2018
  • Table 67: Head And Neck Cancer - Pipeline by 4SC AG, H1 2018
  • Table 68: Head And Neck Cancer - Pipeline by AbbVie Inc, H1 2018
  • Table 69: Head And Neck Cancer - Pipeline by Abion Inc, H1 2018
  • Table 70: Head And Neck Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018

List of Figures

  • Figure 1: Number of Products under Development for Head And Neck Cancer, H1 2018
  • Figure 2: Number of Products under Development by Companies, H1 2018
  • Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
  • Figure 4: Number of Products by Top 10 Targets, H1 2018
  • Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Figure 10: Number of Products by Top 10 Molecule Types, H1 2018
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top